The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Spirin N.N.

Yaroslavl State Medical University

Kiseleva E.V.

Yaroslavl State Medical University

Spirina N.N.

Yaroslavl State Medical University

Neurofilament light chain: a diagnostic potential for multiple sclerosis

Authors:

Spirin N.N., Kiseleva E.V., Spirina N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6): 115‑119

DOI: 10.17116/jnevro2024124061115

Read: 1048 times

Download PDF (RU)
Contact the author
Table of contents

NEUROFILAMENT LIGHT CHAIN: A DIAGNOSTIC POTENTIAL FOR MULTIPLE SCLEROSIS
NEUROFILAMENT LIGHT CHAIN: A DIAGNOSTIC POTENTIAL FOR MULTIPLE SCLEROSIS

To cite this article:

Spirin NN, Kiseleva EV, Spirina NN. Neurofilament light chain: a diagnostic potential for multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):115‑119. (In Russ.)
https://doi.org/10.17116/jnevro2024124061115

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Glial fibrillary acidic protein: is there a rela­tionship with the course of multiple scle­rosis and traumatic brain injury before the onset of multiple scle­rosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84
An indi­vidual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102
Surgical treatment of seco­ndary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209
Quality of life of patients with multiple scle­rosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Abstract:

OBJECTIVE

To evaluate the influence of disease activity, the degree of patient disability and pathogenetic therapy on the concentration of neurofilament light chain (NFL) in the blood serum of patients with multiple sclerosis (MS).

MATERIAL AND METHODS

One hundred and fourteen patients (84 women and 30 men) with definite MS were examined. The concentration of NFL in the blood serum of patients with MS was determined by enzyme immunoassay. The level of NFL was analyzed depending on the characteristics of the course and activity of the demyelinating process, the severity of neurological disorders as well as disease modifying drugs (DMDs).

RESULTS

An NFL level equal to or greater than 4201 pg/ml was found to be associated with a higher risk of developing a clinical exacerbation in the next 4 months. In patients with progression of disability over the next 2 years, the initial concentration of NFL was significantly higher than in the group with a stable EDSS score. The NFL level (4943 pg/ml and higher), which may be a predictor of increased disability in the next two years, was established.

CONCLUSION

The study demonstrates the possibility of using serum NFL levels as a diagnostic marker of possible exacerbation, as well as predicting disability in patients with MS.

Keywords:

multiple sclerosis
aggressive course of multiple sclerosis
neurofilament light chains

Authors:

Spirin N.N.

Yaroslavl State Medical University

Kiseleva E.V.

Yaroslavl State Medical University

Spirina N.N.

Yaroslavl State Medical University

Received:

11.02.2024

Accepted:

18.02.2024

Close metadata

References:

  1. Kouchaki E, Dashti F, Mirazimi SMA, et al. Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis. EXCLI J. 2021;20:1308-1325.
  2. Williams T, Zetterberg H, Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. J Neurol. 2021;268(9):3212-3222. https://doi.org/10.1007/s00415-020-09917-x
  3. Alifirova VM, Kamenskikh EM, Koroleva ES. Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis. S.S. Korsakov Journal of Neurologiy and Psychiatry. 2019;119(10-2):7-13. (In Russ.). https://doi.org/10.17116/jnevro2019119107
  4. Gafson AR, Barthélemy NR, Bomont P, et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020;143(7):1975-1998. https://doi.org/10.1093/brain/awaa098
  5. Domingues RB, Fernandes GBP, Leite FBVM, et al. Neurofilament light chain in the assessment of patients with multiple sclerosis. Arq Neuropsiquiatr. 2019;77(6):436-441.  https://doi.org/10.1590/0004-282X20190060
  6. Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857-870.  https://doi.org/10.1002/ana.24954
  7. Lee Y, Lee BH, Yip W, et al. Neurofilament proteins as prognostic biomarkers in neurological disorders. Curr Pharm Des. 2020;25(43):4560-4569. https://doi.org/10.2174/1381612825666191210154535
  8. Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28:595-599.  https://doi.org/10.1038/nbt.1641
  9. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.  https://doi.org/10.1002/ana.22366
  10. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.  https://doi.org/10.1016/S1474-4422(17)30470-2
  11. Varhaug KN, Torkildsen Ø, Myhr KM, et al. Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol. 2019;10:338.  https://doi.org/10.3389/fneur.2019.00338
  12. Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016;87(2):126-129.  https://doi.org/10.1136/jnnp-2014-309690
  13. Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25:678-686.  https://doi.org/10.1177/1352458518765666
  14. Wong YYM, Bruijstens AL, Barro C, et al. Serum neurofilament light chain in pediatric M.S and other acquired demyelinating syndromes. Neurology. 2019;93:e968-e974. https://doi.org/10.1212/WNL.0000000000008057
  15. Bjornevik K, Munger KL, Cortese M, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 2020;77(1):58-64.  https://doi.org/10.1001/jamaneurol.2019.3238
  16. Dalla Costa G, Martinelli V, Sangalli F, et al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology. 2019;92:e733-e741. https://doi.org/10.1212/WNL.0000000000006902
  17. Kuhle J, Kropshofer H, Haring DA, et al. Neurofilament light levels in the blood of patients with secondary progressive MS are higher than in primary progressive M.S and may predict brain atrophy in both M.S subtypes. Mult Scler J. 2018;24:111.  https://doi.org/10.1177/1352458518798579
  18. Häring DA, Kropshofer H, Kappos L, et al. Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e856. https://doi.org/10.1212/NXI.0000000000000856
  19. Cantó E, Barro C, Zhao C, et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. 2019;76:1359-1366. https://doi.org/10.1001/jamaneurol.2019.2137
  20. Frers RA, Otero-Losada M, Kobiec T, et al. Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis. Front Immunol. 2022;13:912005. https://doi.org/10.3389/fimmu.2022.912005
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.